Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.180
+0.030 (1.40%)
At close: May 20, 2026, 4:00 PM EDT
2.180
0.00 (0.00%)
After-hours: May 20, 2026, 4:10 PM EDT

Grace Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
3431----
Market Cap Growth
10.97%-----
Enterprise Value
14.69.140000
Last Close Price
2.182.28----
PB Ratio
0.510.47----
P/TBV Ratio
0.530.41----
Debt / Equity Ratio
-000.010.000
Net Debt / Equity Ratio
-0.29-0.33-0.37-0.40-0.40-1.09
Net Debt / EBITDA Ratio
1.661.331.790.532.783.91
Net Debt / FCF Ratio
1.841.491.861.722.524.22
Quick Ratio
14.5611.5314.098.4113.5638.80
Current Ratio
14.9611.7714.268.5913.8939.50
Return on Equity (ROE)
-10.22%-14.91%-19.82%-48.15%-18.23%-57.33%
Return on Assets (ROA)
-14.82%-17.21%-14.76%-40.99%-15.64%-38.49%
Return on Invested Capital (ROIC)
-19.88%-25.90%-23.31%-65.66%-36.43%-2149.08%
Return on Capital Employed (ROCE)
-17.79%-23.54%-17.45%-51.88%-16.74%-43.02%
Buyback Yield / Dilution
-36.09%-26.85%-28.16%-21.09%-148.46%-40.25%
Total Shareholder Return
-36.09%-26.85%-28.16%-21.09%-148.46%-40.25%
Updated Feb 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q